Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Invitae Corporation    NVTA

INVITAE CORPORATION

(NVTA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2019 216 M
EBIT 2019 -218 M
Net income 2019 -233 M
Finance 2019 98,3 M
Yield 2019 -
Sales 2020 329 M
EBIT 2020 -233 M
Net income 2020 -241 M
Debt 2020 21,5 M
Yield 2020 -
P/E ratio 2019 -7,62x
P/E ratio 2020 -7,93x
EV / Sales2019 8,31x
EV / Sales2020 5,82x
Capitalization 1 895 M
More Financials
Company
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their... 
More about the company
Surperformance© ratings of Invitae Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INVITAE CORPORATION
01/13INVITAE CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
2019INVITAE : to Present at the 38th Annual J.P. Morgan Healthcare Conference
PR
2019INVITAE : Announces Program with BioMarin to Expand Access to Genetic Testing fo..
PR
2019INVITAE : to Participate in the 31st Annual Piper Jaffray Healthcare Conference
PR
2019INVITAE CORP : Entry into a Material Definitive Agreement, Completion of Acquisi..
AQ
2019INVITAE : to Acquire Clear Genetics
PR
2019INVITAE : University of Vermont Health Network begins offering Genomic DNA Testi..
PR
2019INVITAE : 3Q Earnings Snapshot
AQ
2019INVITAE : Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples
PU
2019INVITAE CORP : Results of Operations and Financial Condition (form 8-K)
AQ
2019INVITAE : Highlights Importance of Medical Genetics, Honors Excellence in Geneti..
PR
2019INVITAE : to announce third quarter 2019 financial results on November 6, 2019
PR
2019INVITAE : Research presented by Invitae at the American Society of Human Genetic..
PU
2019INVITAE CORP : Financial Statements and Exhibits (form 8-K)
AQ
2019INVITAE CORP : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
More news
News in other languages on INVITAE CORPORATION

- No features available -

More news
Sector news : Bio Diagnostics & Testing
01/14Freeport Rules Out Deals in Near Term -- WSJ
DJ
01/13Freeport-McMoran Isn't Looking for Strategic Deals in Coming Years, CEO Says
DJ
01/13Novartis to speed access to $10 billion heart drug via NHS deal
RE
01/13Drugmakers Test New Ways to Pay for Six-Figure Treatments
DJ
01/08In a vigorous defense, Carlos Ghosn claims he has done nothing wrong
More sector news : Bio Diagnostics & Testing
Chart INVITAE CORPORATION
Duration : Period :
Invitae Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVITAE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 28,57  $
Last Close Price 19,63  $
Spread / Highest target 63,0%
Spread / Average Target 45,5%
Spread / Lowest Target 1,88%
EPS Revisions
Managers
NameTitle
Sean Emerson George Chairman, President & Chief Executive Officer
Elias Lee Bendekgey Chief Operating Officer & Secretary
Shelly D. Guyer Chief Financial & Accounting Officer
Robert Nussbaum Chief Medical Officer
Eric I. Aguiar Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INVITAE CORPORATION21.70%1 895
GUARDANT HEALTH, INC.8.27%7 944
GENSCRIPT BIOTECH CORPORATION6.09%4 551
IOVANCE BIOTHERAPEUTICS, INC.-13.75%3 013
VERACYTE, INC.7.99%1 473
MIRACA HOLDINGS INC.1.69%1 402